Titel

Merkliste
1 Ergebnisse

Vedolizumab as first-line biological therapy in elderly pat..:

Mohamed Attauabi (10149049) ; Camilla Höglund (11078243) ; Janne Fassov (11078246)...
https://figshare.com/articles/journal_contribution/Vedolizumab_as_first-line_biological_therapy_in_elderly_patients_and_those_with_contraindications_for_anti-TNF_therapy_a_real-world_nationwide_cohort_of_patients_with_inflammatory_bowel_diseases/14912705. , 2021

Link: https://doi.org/10.6084/m9.figshare.14912705.v1

RT Journal
T1 <Title>Vedolizumab as first-line biological therapy in elderly patients and those with contraindications for anti-TNF therapy: a real-world, nationwide cohort of patients with inflammatory bowel diseases</Title>

UL https://suche.suub.uni-bremen.de/peid=base-ftsmithonian:oai:figshare.com:article_14912705&Exemplar=1&LAN=DE
				
A1 Mohamed Attauabi (10149049)
A1 Camilla Höglund (11078243)
A1 Janne Fassov (11078246)
A1 Kenneth Bo Pedersen (11078249)
A1 Heidi Bansholm Hansen (11078252)
A1 Signe Wildt (3241044)
A1 Michael Dam Jensen (4512367)
A1 Anders Neumann (11078255)
A1 Cecilie Lind (11078258)
A1 Henrik Albaek Jacobsen (11078261)
A1 Ana-Maria Popa (1894489)
A1 Jens Kjeldsen (4512376)
A1 Natalia Pedersen (590118)
A1 Akbar Molazahi (11078264)
A1 Kent Haderslev (11078267)
A1 Claus Aalykke (11078270)
A1 Torben Knudsen (597608)
A1 Wojciech Cebula (11078273)
A1 Pia Munkholm (5477291)
A1 Flemming Bendtsen (635846)
A1 Jakob Benedict Seidelin (11078276)
A1 Johan Burisch (590117)
YR 2021
K1 Medicine
K1 Pharmacology
K1 Biotechnology
K1 Ecology
K1 Immunology
K1 Hematology
K1 Space Science
K1 Biological Sciences not elsewhere classified
K1 Mathematical Sciences not elsewhere classified
K1 Chemical Sciences not elsewhere classified
K1 Information Systems not elsewhere classified
K1 Inflammatory bowel disease
K1 ulcerative colitis
K1 Crohn's disease
K1 vedolizumab
K1 real-world
K1 efficacy
K1 safety
K1 first-line biologics
K1 bio-naïve
K1 nationwide
K1 population-based
JF https://figshare.com/articles/journal_contribution/Vedolizumab_as_first-line_biological_therapy_in_elderly_patients_and_those_with_contraindications_for_anti-TNF_therapy_a_real-world_nationwide_cohort_of_patients_with_inflammatory_bowel_diseases/14912705
LK http://dx.doi.org/https://doi.org/10.6084/m9.figshare.14912705.v1
DO https://doi.org/10.6084/m9.figshare.14912705.v1
SF ELIB - SuUB Bremen

Export

RefWorks (nur Desktop-Version!)
Flow (Zuerst in Flow einloggen, dann importieren)